title: [How many harmed by rofecoxib in Germany?].
authors.forename: Elke
authors.initials: E
authors.lastname: Scharnetzky
authors.forename: Frank
authors.initials: F
authors.lastname: Andersohn
authors.forename: Walter
authors.initials: W
authors.lastname: Schill
authors.forename: Edeltraut
authors.initials: E
authors.lastname: Garbe
authors.forename: Iris
authors.initials: I
authors.lastname: Pigeot
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000401:mortality; D016022:Case-Control Studies; D015331:Cohort Studies; D016001:Confidence Intervals; D018849:Controlled Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D019992:Databases as Topic; D005858:Germany; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D008962:Models, Theoretical; D009203:Myocardial Infarction / Q000139:chemically induced / Q000401:mortality; D011446:Prospective Studies; D012306:Risk; D013450:Sulfones / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib